The primary objectives of CIS Biotech, Inc. include:the discovery of disease-associated biomarkers, and the development of diagnostic tests for the commercial use of unique products in the in-vitro diagnostic (IVD) market segments of Life Science Research, Diagnostics and Laboratory Services, in accordance with the dynamics of the industry and the highest standards of excellence and integrity.

CIS Biotech, Inc has Clinical Laboratory Improvement Amendments (CLIA) certification and Georgia State License for Gold Dot NR2 Peptide test and Gold Dot NR2 Antibody test. Both tests have CE mark. Both test can also be sold for research use only in the USA. CIS Biotech, Inc. will consider strategic alliances with Original Equipment Manufacturer's and reference laboratories, to access resources for clinical validation of IVD products, U.S. Food and Drug Administration clearance.

The company intends to license its intellectual property concerning brain biomarkers and technology to strategic partners possessing OEM technologies. It further intends to outsource the manufacturing of IVD products. The company is also pursuing partnerships with marketing and distribution organizations experienced in selling test kits to laboratories, institutions and hospitals for research purposes only.